Ariceum Therapeutics

Inactive

Ariceum Therapeutics creates systemic targeted radiotherapy (STR) agents that combine tumor‑specific ligands with alpha‑emitting isotopes, delivering potent, short‑range radiation while enabling real‑time PET or SPECT imaging. This integrated diagnostic‑therapeutic approach aims to improve precision, reduce off‑target toxicity, and expand treatment options for metastatic cancers such as small‑cell lung cancer and Merkel cell carcinoma.

Traction 10/10

Berlin, Germany · HQ

Founded 2021235K+ followers

Biotechnology

Updated 5 months ago

Funding

Raised to date

$25MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

2 founders

Manfred Ruediger

CEO

Serge SAGODIRA

Unknown

Product

Problem

Current cancer treatments often lack the ability to simultaneously visualize tumors and deliver highly localized radiation, leading to systemic side effects and limited efficacy for metastatic disease.

Solution

Ariceum Therapeutics develops systemic targeted radiotherapy (STR) agents that combine diagnostic imaging and therapeutic radiation in a single radiopharmaceutical. By conjugating tumor‑specific ligands to alpha‑emitting isotopes, the platform delivers potent, short‑range radiation directly to cancer cells while enabling real‑time PET or SPECT imaging to monitor distribution and response. The approach aims to improve treatment precision, reduce off‑target toxicity, and expand therapeutic options for hard‑to‑treat cancers such as small‑cell lung cancer and Merkel cell carcinoma. Clinical programs evaluate safety, biodistribution, and efficacy of these agents in early‑phase trials.

Target Audience

Primary customers are oncology clinicians and pharmaceutical partners developing targeted radiopharmaceutical therapies for metastatic and refractory cancers.

Features

Alpha‑emitting radionuclides (e.g., ^225Ac) linked to tumor‑targeting molecules for high‑LET radiation delivery
Integrated imaging capability using isotopic signatures for PET/SPECT visualization of drug uptake
Modular ligand platform allowing adaptation to multiple tumor antigens
Optimized pharmacokinetics to achieve systemic circulation with rapid tumor accumulation and clearance from healthy tissue
Manufacturing process compliant with GMP for clinical‑grade radiopharmaceutical production